Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 12/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.52 |
| ▸ | CDK2 | P24941 | 4/20 | 0.52 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 2/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6396640 | 0.84 | FLT3 (0.65) | FLT3PDGFRACDK2CCNE1NPC1 | |
| SCHEMBL5194070 | 0.83 | FLT3 (0.64) | FLT3PDGFRACDK2CCNE1NPC1 | |
| SCHEMBL5197599 | 0.83 | FLT3 (0.55) | FLT3PDGFRACDK2CCNE1NPC1 | |
| SCHEMBL5192781 | 0.82 | NPC1 (0.62) | FLT3PDGFRACDK2CCNE1NPC1 | |
| SCHEMBL5195445 | 0.82 | SCTR (0.63) | FLT3PDGFRACDK2CCNE1NPC1 | |
| SCHEMBL5195304 | 0.81 | FLT3 (0.69) | FLT3PDGFRACDK2CCNE1NPC1 | |
| SCHEMBL5193681 | 0.81 | FLT3 (0.75) | FLT3PDGFRACDK2CCNE1SRC | |
| SCHEMBL5193671 | 0.81 | FLT3 (0.75) | FLT3PDGFRACDK2CCNE1SRC | |
| SCHEMBL5196062 | 0.81 | NPC1 (0.60) | FLT3PDGFRACDK2CCNE1NPC1 | |
| SCHEMBL5195256 | 0.81 | FLT3 (0.60) | FLT3PDGFRACDK2CCNE1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1183256-B1 | PURINE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA SA (FR) | 2007-08-22 | — | — | EP | disclosed |
| US-7208598-B2 | Derivatives of purine, their preparation process and pharmaceutical compositions containing them | AVENTIS PHARMA (FR) | 2007-04-24 | — | — | US | disclosed |
| US-7122669-B1 | Purine derivatives, preparation method and pharmaceutical compositions containing same | HOECHST MARION ROUSSEL (FR) | 2006-10-17 | — | — | US | disclosed |
| US-20050187228-A1 | Derivatives of purine, their preparation process and pharmaceutical compositions containing them | AVENTIS PHARMA S.A. | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187228-A1 | Derivatives of purine, their preparation process and pharmaceutical compositions containing them | CDK6, CDK1, CDK2 | FLT3 719/4885PDGFRA 1525/4885CDK2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.